Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

AGEN 2.96 +0.01 (0.34%)
price chart
Why Agenus Inc. Shares Tumbled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
GSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non-Small Cell ...  Business Wire (press release)
Glaxo Cancer Vaccine Fails, Testing Continues  Fox Business
Related articles »  
Why Agenus Inc. Stock Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Agenus Rallies On Brain Cancer Vaccine Results  Bidness Etc
Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data ...  Business Wire (press release)
Related articles »  
Analyst Update on Short Term Price Target:Agenus Inc , Pzena Investment ...
Agenus Inc (NASDAQ:AGEN): 1 analysts have set the short term price target of Agenus Inc (NASDAQ:AGEN) at $6. The standard deviation of short term price target has been estimated at $0, implying that the actual price may fluctuate by this value.
Company High Short Interest:Anacor Pharmaceuticals , Agenus Inc
Shares of Anacor Pharmaceuticals (NASDAQ:ANAC) are trading at $32.55. The price is 3.6% off the 52-week high and 61.1% off the 52-week low.
Related articles »  
Why Agenus Inc. Stock Briefly Spiked Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
UPDATE: Agenus Vaccine Shows Significant Reduction in Viral Burden after ...  Benzinga
Maxim Keeps Agenus (AGEN) at Buy, Comments on HerpV Phase 2 Results  StreetInsider.com (subscription)
Related articles »  
Agenus Inc - A Potential New Play On Ebola
Shares of Agenus Inc (NASDAQ: AGEN) have moved to the upside in Monday's trade as the company is being mentioned as a potential play on Ebola.
Related articles »  
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine
Agenus Inc. (AGEN), headquartered in Lexington, Massachusetts, is an immune-oncology biopharmaceutical company focused on the development of innovative technologies and products aimed at treating cancers and infectious disease by helping the ...
Agenus Reports Second Quarter 2014 Financial Results  MarketWatch
Related articles »  
Morning Movers: PVH Corp. (PVH), Agenus Inc. (AGEN), Cheniere Energy, Inc ...
Agenus Inc. (NASDAQ:AGEN) of the Healthcare sector (Biotechnology) has gained 1.70% per share early this morning. Agenus Inc. (AGEN) is currently at $2.99 with a market cap of 185, volume of 079,418 shares and a weekly performance of - 0.670%.
Related articles »  
Agenus Inc. (AGEN) Jumps 8.46% on October 15
Agenus Inc. (AGEN) was among the biggest gainers on the Russell 2000 for October 15 as the stock popped 8.46% to $2.95, representing a gain of $0.23 per share.
UTHSC Tests Agenus Inc.'s New Immune Boosting Melanoma Therapies
Agenus Inc. has announced the initiation of the Phase 2 clinical trial at the University of Texas Health Science Center at Houston to test its immune boosting melanoma drugs.
Related articles »